What is Evommune 's new issues (in shares)?

Evommune (EVMN) reported new issues (in shares) of 220M in Q1 2025.

What does new issues (in shares) mean?

The total number of common shares issued by the company to external parties during the reporting period, excluding shares issued for stock-based compensation or conversions. This metric provides insight into the company's equity-based capital raising activities and the potential for shareholder dilution.

Evommune EVMN New issues (in shares)

New issues (in shares) at other companies

Diversified Energy DEC

8.5M—

Evommune EVMN

220M—

PopularBPOP

15.3K-22.5%

EyePoint, Inc. EYPT

2.2M—

ARD

Ardent Health PartnersARDT

7.6K—

TMC the metals company Inc.TMC

4.2M-89.1%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodSharesNewIssues.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's new issues (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's new issues (in shares)?: Evommune (EVMN) reported new issues (in shares) of 220M in Q1 2025.
What does new issues (in shares) mean?: The total number of common shares issued by the company to external parties during the reporting period, excluding shares issued for stock-based compensation or conversions. This metric provides insight into the company's equity-based capital raising activities and the potential for shareholder dilution.